Evidence map›Paper›PMID 40399531›Full record

ArticleAnnals of hematology2025

Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia with myelodysplasia-related gene mutations under low-intensity therapy.

Jinya Lin, Xiupu Liu, Shuangwei Ying, Yuanyuan Zhu, Weijia Huang, Weiyan Zheng, Xiujin Ye, Jimin Shi, Yi Luo, Jingsong He and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jinya Lin *Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Xiupu Liu *Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Shuangwei Ying *Department of Hematology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.
Yuanyuan ZhuBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Weijia HuangBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Weiyan ZhengBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Xiujin YeBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Jimin ShiBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yi LuoBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Jingsong HeBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Zhen CaiBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yi ZhaoBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Wenjun WuBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Donghua HeBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Xiaoyan HanBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Gaofeng ZhengBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yanmin ZhaoBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yongxian HuBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
He HuangBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. huanghe@zju.edu.cn.
Jie SunBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Institute of Hematology, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. jsun1492@zju.edu.cn.

Funding

The Department of Science and Technology of Zhejiang Province 2023R01012
6 · The paper itself

Abstract

According to the 2022 International Consensus Classification (ICC) guidelines, nine myelodysplasia-related (MDS-related) gene mutations are classified as adverse-risk markers in acute myeloid leukemia (AML) under intensive therapy (INT). Although venetoclax (VEN) has demonstrated clinical benefit in subsets of AML with MDS-related gene mutations (AML-MR), its efficacy across all nine mutations remains unclear. In this retrospective study involving 453 AML-MR patients, the overall composite complete remission (CRc) rate was 62.6% (275/439). Among fit patients receiving INT, 57.7% (86/149) achieved CRc after a single cycle of induction therapy (IND1), while 62.7% (79/126) of unfit patients receiving low-intensity therapy (LIT) achieved CRc after IND1. VEN significantly improved CRc rates in unfit patients treated with LIT (45.9% vs. 30.0%, P = 0.002), but not in fit patients receiving INT (61.1% vs. 45.0%, P = 0.052). In both groups, CRc after IND1 was strongly associated with improved overall survival (OS). Subgroup analysis showed that hematopoietic stem cell transplantation (HSCT) significantly prolonged OS and relapse-free survival (RFS) in patients without favorable-risk cytogenetics (P = 0.002 for OS, P < 0.001 for RFS), but conferred no survival benefit in those with favorable-risk cytogenetics (P = 0.119 for OS, P = 0.437 for RFS). These findings support the use of VEN to enhance early remission and survival outcomes in unfit AML-MR patients and suggest that HSCT should be considered primarily in those lacking favorable-risk cytogenetics.

Indexed as

Antineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteMutationMyelodysplastic SyndromesSulfonamidesAdultAgedAged, 80 and overFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedRemission InductionRetrospective StudiesAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclaxAcute myeloid leukemiaHematopoietic stem cell transplantationIntensive therapyLow-intensity therapyMyelodysplasia-related gene mutationVenetoclax

Identifiers

PMID40399531
PMCPMC12141368

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.